Navigation Links
WuXi PharmaTech Announces First-Quarter 2009 Results
Date:5/14/2009

SHANGHAI, China, May 14 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for first-quarter 2009.

    (Logo:http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

    Highlights
    -- First-Quarter 2009 Net Revenues Increase 5% Year Over Year to
       $59.1 Million
    -- Laboratory Services Net Revenues Grow 33% Year Over Year to
       $56.5 Million, Driven by Organic Growth and the AppTec Acquisition
    -- China-Based Laboratory Services Net Revenues Grow 28% Year Over Year
       to $41.6 Million
    -- GAAP Diluted Earnings Per ADS of 16 Cents
    -- Non-GAAP Diluted Earnings Per ADS of 20 Cents
    -- Company Reconfirms 2009 Financial Guidance, Including 15-20% Net
       Revenue Growth in China-Based Laboratory Services

Management Comment

"WuXi PharmaTech got off to a good start in 2009 with solid first-quarter results," said Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "We achieved 33% year-over-year growth in Laboratory Services revenues, reflecting 28% growth in China-based Laboratory Services and the contribution of the AppTec acquisition on a year-over-year basis. Revenues in our U.S.-based Laboratory Services and China-based Manufacturing Services businesses were in line with our expectations and reflected the challenging operating environment. We remain on target to achieve our 2009 financial guidance, including 15-20% revenue growth in China-based Laboratory Services.

"We are expanding our platform of integrated services to help our customers advance their drug candidates as quickly and efficiently as possible. While our core discovery chemistry business continued its solid growth, we are seeing even stronger growth in newer capabilities such as discovery biology, DMPK (drug metabolism and pharmacokinetics)/ADME (absorption, distribution, metabolism, and excretion), process research, and bioanalytical services. We are pleased to have recently completed an FDA inspection of our bioanalytical testing laboratory in China without major observations for noncompliance issues.

"We are investing in an even broader suite of services to drive accelerated revenue growth in 2010 and beyond. We are planning capital expenditures of $50-60 million in 2009, the majority targeted for upgrading and expanding the facilities in our China-based Laboratory Services business to support the business growth. With the construction of a new facility in Jinshan, we have now expanded our manufacturing capability to commercial scale, with the aim of producing key ingredients for late-stage clinical trials and commercial supplies. We continue to invest in our Suzhou facility with the aim of becoming the leading China-based service provider in drug safety evaluation.

"Our mission as a company is to partner with the world's leading life science and medical device companies to help them improve the success of research and shorten the time of development," Dr. Li concluded.

GAAP Results

First-quarter 2009 net revenues grew 5% year over year to $59.1 million, driven primarily by 28% growth in revenues for China-based Laboratory Services, offset by an 81% decline in Manufacturing Services revenues. China-based Laboratory Services benefited from strong demand year over year, as life science companies increasingly acted to reduce cost and improve productivity by outsourcing R&D services. Revenue in Manufacturing Services is inherently variable due to the size of this business. The year-over-year decline in Manufacturing Services revenue resulted from project delays that postponed work authorization and delivery. In addition, the majority of Manufacturing Services revenue in first-quarter 2008 came from a single non-recurring project. On a pro-forma basis, including January 2008 revenues of $5 million, U.S. testing revenues declined 1% in the quarter to $14.9 million on a year-over-year basis.

First-quarter 2009 GAAP gross profit declined 11% year over year to $23.3 million, mainly due to a decline in the gross-profit contribution of Manufacturing Services, offset by increased contribution from China-based Laboratory Services. First-quarter 2009 GAAP gross margin declined to 39% from 47% in the first quarter of 2008 due to declines in gross margin in China-based Laboratory Services, in the U.S. Laboratory Services business due to project mix, and in Manufacturing Services due to project mix and low capacity utilization.

Declines in first-quarter 2009 GAAP operating income and operating margin and in 2009 GAAP net income and net margin relative to the first quarter of 2008 reflect the same factors as those discussed above, as operating expenses, other income/expenses, and income taxes showed relatively little change year over year. Diluted earnings per ADS in the first quarter of 2009 were 16 cents compared to 19 cents in the first quarter of 2008. Mark-to-market foreign-exchange gains contributed 3.6 cents per share in first-quarter 2009 and 3.7 cents in first-quarter 2008.

Non-GAAP Results

Non-GAAP financial results exclude the impact of share-based compensation expenses, amortization and deferred tax impact of acquired intangible assets, and loss from discontinued operations.

First-quarter 2009 non-GAAP gross profit declined 10% year over year to $24.7 million, mainly due to a decline in the gross profit contribution of Manufacturing Services, offset by increased revenue from China-based Laboratory Services. First-quarter 2009 non-GAAP gross margin declined to 42% from 49% in the first quarter of 2008 due to declines in gross margin in China-based Laboratory Services, in the U.S. Laboratory Services business due to project mix, and in Manufacturing Services due to project mix and low capacity utilization. First-quarter 2009 non-GAAP gross margin increased by three percentage points to 42% compared to non-GAAP gross margin of 39% in the fourth quarter of 2008 due to cost-control efforts.

Declines in first-quarter 2009 non-GAAP operating income and operating margin and in 2009 non-GAAP net income and net margin relative to the first quarter of 2008 reflect the same factors as those discussed above, as operating expenses, other income/expenses, and income taxes showed relatively little change year over year. Non-GAAP diluted earnings per ADS were 20 cents compared to 25 cents in the first quarter of 2008. Mark-to-market foreign-exchange gains contributed 3.6 cents per share in first-quarter 2009 and 3.7 cents in first-quarter 2008.

    (See the table titled "Reconciliation of GAAP to Non-GAAP" below).

    2009 Financial Guidance
    The Company reconfirmed its earlier financial guidance for 2009:
    -- Total net revenues of $265 million-$275 million(1)
    -- Net revenue growth in China-based Laboratory Services of 15-20%
       compared to 2008 China-based Laboratory Services revenue
    -- Manufacturing Services net revenue lower than 2008 Manufacturing
       Services net revenue
    -- U.S. testing (AppTec) net revenue comparable to 2008 U.S. testing
       net revenue on a pro-forma basis(1)
    -- Non-GAAP gross profit and operating income lower than 2008 amounts
       in dollars and as percentages of net revenues as we invest in new
       capabilities and capacities
    -- Adjusted EBITDA (excluding share-based compensation charges and
       potential mark-to-market gains or losses from foreign-currency
       forward contracts) relatively flat with 2008 adjusted EBITDA of
       $72 million
    -- Capital expenditures of $50-$60 million

    (1) Our targeted net revenues of $265 million to $275 million in 2009
        compare with $258.5 million in 2008 from our continuing operations
        on a pro-forma basis (non-GAAP). WuXi PharmaTech acquired AppTec,
        Inc. at the end of January 2008, and our reported results for
        AppTec in the first quarter of 2008 reflect two months of net
        revenues after the acquisition date. The pro-forma revenues include
        the January 2008 revenues from continuing operations of the AppTec
        business.

Commenting on financial performance and guidance, Edward Hu, chief operating officer and acting chief financial officer, said, "Our first-quarter 2009 financial results met our expectations and give us reason to reconfirm our full-year 2009 financial guidance. As anticipated, China-based Laboratory Services revenues grew strongly in the first quarter from continued growth in demand. Manufacturing Services revenues were very light in the quarter due to project delays. Revenue in this business is inherently variable. U.S. testing revenues were essentially flat relative to pro-forma first-quarter 2008 results due to weak economic conditions.

"We expect second-quarter 2009 revenues to grow 8-10% from first-quarter 2009 revenues. Manufacturing Services revenues should improve somewhat from the first quarter but remain very light in the second quarter ($4-5 million). Second-quarter total company gross profit margin is expected to be comparable to the first quarter."



                          WUXI PHARMATECH (CAYMAN) INC.
                      UNAUDITED CONSOLIDATED BALANCE SHEETS
              (in thousands of U.S. Dollars, except ordinary share, ADS
                              and par value data)

                                                       March 31,  December 31,
                                                         2009         2008

    Assets:
    Current assets:
      Cash and cash equivalents                         101,885       56,624
      Restricted cash                                     2,696        1,338
      Short-term investment                                  --       14,631
      Accounts receivable, net                           38,423       36,457
      Inventories                                         7,526        6,926
      Prepaid expenses and other current assets           9,592        7,281
      Assets of discontinued operations (Note 1)          3,754        6,508
         Total current assets                           163,876      129,765
    Non-current assets:
      Goodwill                                           23,956       23,956
      Property, plant and equipment, net                159,742      152,704
      Intangible assets, net                              9,077        9,934
      Prepaid land use rights                             5,394        5,424
      Deferred tax assets                                 9,026        8,807
      Other non-current assets                            5,792        5,809
         Total non-current assets                       212,987      206,634

         Total assets                                   376,863      336,399

    Liabilities and shareholders' equity:
    Current liabilities:
      Short-term and current portion of long-term debt   41,502        7,558
      Accounts payable                                   17,538       19,829
      Accrued expenses                                    9,250       14,279
      Deferred revenue                                    3,825        3,373
      Advanced subsidies                                  2,369        3,080
      Other taxes payable                                 6,596        5,742
      Other current liabilities                           4,391        3,448
      Liabilities of discontinued operations (Note 1)       196        1,495
         Total current liabilities                       85,667       58,804
    Non-current liabilities:
      Long-term debt, excluding current portion           2,240        2,305
      Advanced subsidies                                  1,782        1,819
      Convertible notes                                  35,864       35,864
      Other non-current liabilities                       6,770        6,731
         Total non-current liabilities                   46,656       46,719

         Total liabilities                              132,323      105,523

    Shareholders' equity:
      Ordinary shares ($0.02 par value, 5,002,550,000
       authorized, 540,563,086 and 529,385,590 issued
       and outstanding as of March 31, 2009, and
       December 31, 2008, respectively)                  10,811       10,588
      Additional paid-in capital                        326,655      324,629
      Accumulated deficit                              (109,770)    (121,505)
      Accumulated other comprehensive income             16,844       17,164
         Total shareholders' equity                     244,540      230,876

       Total liabilities and shareholders' equity       376,863      336,399

      Note 1: The biologics manufacturing operations in Philadelphia, which
              management decided to close in December 2008, were classified as
              discontinued operations.



                          WUXI PHARMATECH (CAYMAN) INC.
            UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
         (In thousands of U.S. dollars, except ADS data and per ADS data)

                                                    Three Months Ended
                                                         March 31,
                                                      2009     2008       %
                                                             (Note 3)  Change
    Net revenues:
    Laboratory Services (Note 2)                     56,596     42,515     33%
    Manufacturing Services                            2,552     13,652    (81%)
    Total net revenues                               59,148     56,167      5%

    Cost of revenues:
    Laboratory Services (Note 2)                    (33,856)   (22,603)    50%
    Manufacturing Services                           (1,973)    (7,367)   (73%)
    Total cost of revenues                          (35,829)   (29,970)    20%

    Gross profit:
    Laboratory Services (Note 2)                     22,740     19,912     14%
    Manufacturing Services                              579      6,285    (91%)
    Total gross profit                               23,319     26,197    (11%)

    Operating expenses:
    Selling and marketing expenses                   (1,334)    (1,354)    (1%)
    General and administrative expenses             (11,710)   (11,137)     5%
    Total operating expenses                        (13,044)   (12,491)     4%

    Operating income                                 10,275     13,706    (25%)
    Other income (expenses), net:
    Other income (expenses), net                      3,393      2,807     21%
    Interest income (expenses), net                     (50)       516   (110%)
    Total other income (expenses), net                3,343      3,323      1%

    Income from continuing operations before income
     taxes                                           13,618     17,029    (20%)
    Income tax expenses                              (1,883)    (1,861)     1%
    Income from continuing operations                11,735     15,168    (23%)

    Loss on discontinued operations, net (Note 1)
    Loss from operations of discontinued component       --     (2,044)      *
    Income tax benefit                                   --        737       *
    Loss on discontinued operations                      --     (1,307)      *
    Net income                                       11,735     13,861    (15%)

    Basic net earnings (loss) per ADS:
    Earnings from continuing operations                0.18       0.25    (29%)
    Loss on discontinued operations-net of tax
     (Note 1)                                            --      (0.03)      *
    Net earnings per ADS                               0.18       0.22    (22%)

    Weighted average ADS outstanding-basic       67,013,222  61,895,469


    Diluted net earnings (loss) per ADS:
    Earnings from continuing operations                0.16       0.21    (23%)
    Loss on discontinued operations-net of tax
     (Note 1)                                            --      (0.02)      *
    Net earnings per ADS                               0.16       0.19    (16%)

    Weighted average ADS outstanding-diluted     72,700,738 72,416,243


    *  Not meaningful

    Note 2: First-quarter 2009 net revenues for Laboratory Services were
            comprised of $41.6 million for China-based Laboratory Services and
            $14.9 million for U.S. testing. The first-quarter 2008 amount was
            comprised of $32.4 million for China-based Laboratory Services and
            $10.1 million for U.S. testing.
    Note 3: Financial results of AppTec were consolidated as of January 31,
            2008.



                          WUXI PHARMATECH (CAYMAN) INC.
                       RECONCILIATION OF GAAP TO Non-GAAP
       (in thousands of U.S. Dollars, except ADS data and par value data)

                                                   Three Months Ended
                                                         March 31,
                                                     2009        2008    %
    GAAP gross profit                              23,319      26,197   (11%)
    GAAP gross margin                                 39%         47%
    Adjustments
    Share-based compensation                          591         699
    Amortization of acquired intangible assets        764         384
    Non-GAAP gross profit                          24,674      27,280   (10%)
    Non-GAAP gross margin                             42%         49%

    GAAP operating income                          10,275      13,706   (25%)
    GAAP operating margin                             17%         24%
    Adjustments
    Share-based compensation                        1,999       2,978
    Amortization of acquired intangible assets        764         384
    Non-GAAP operating income                      13,038      17,068   (24%)
    Non-GAAP operating margin                         22%         30%

    GAAP net income                                11,735      13,861   (15%)
    GAAP net margin                                   20%         25%
    Adjustments:
    Share-based compensation                        1,999       2,978
    Amortization of acquired intangible assets        764         384
    Deferred tax impact related to acquired
     intangible assets                               (296)       (151)
        Loss from discontinued operations              --       1,307
    Non-GAAP net income                            14,202      18,379   (23%)
    Non-GAAP net margin                               24%         33%

    GAAP net income                                11,735      13,861   (15%)
    Add back:
    Depreciation and amortization                   5,007       4,855
    Interest (income) expenses, net                    50        (516)
    Income tax expenses                             1,883       1,124
    EBITDA                                         18,675      19,324    (3%)
    Adjustments
    Share-based compensation                        1,999       2,978
        Mark-to-market gain from
         foreign-currency forward contracts        (2,621)     (2,683)
    Adjusted EBITDA                                18,053      19,619    (8%)

    Income attributable to holders of ADS
     (Non-GAAP):
    Basic                                          14,202      18,379   (23%)
    Diluted                                        14,202      18,379   (23%)

    Basic earnings per ADS (Non-GAAP)                0.21        0.30   (29%)
    Diluted earnings per ADS (Non-GAAP)              0.20        0.25   (23%)

    Weighted average ADS outstanding - basic
     (Non-GAAP)                                67,013,222  61,895,469
    Weighted average ADS outstanding - diluted
     (Non-GAAP)                                72,700,738  72,416,243


                          WUXI PHARMATECH (CAYMAN) INC.
                       REVENUE RECONCILIATION BY GEOGRAPHY
                         (in thousands of U.S. Dollars)
                                                  Three Months Ended
                                                      March 31,
                                                  2009       2008         %

    Net revenues:
    China-based Laboratory Services              41,648     32,418       28%
    China-based Manufacturing Services            2,552     13,652      (81%)
    Subtotal                                     44,200     46,070       (4%)
    U.S.-based Laboratory Services               14,948     10,097       48%
    Total net revenues                           59,148     56,167        5%

Conference Call

WuXi PharmaTech senior management will host a conference call at 8:00 am (Eastern) / 5:00 am (Pacific) / 8:00 pm (Beijing/Shanghai/Hong Kong) on Friday, May 15, 2009, to discuss its first-quarter 2009 financial results and future prospects. The conference call may be accessed by calling:

    United States:    1-866-519-4004
    China (Landline): 800-819-0121
    China (Mobile):   400-620-8038
    Hong Kong:        800-933-053
    United Kingdom:   0-808-234-6646
    International:    +65-6735-7955
    Conference ID:    96870349
    Web PIN:          8656

A telephone replay will be available two hours after the call's completion at:

    United States:  1-866-214-5335
    China North:    10-800-714-0386
    China South:    10-800-140-0386
    Hong Kong:      800-901-596
    United Kingdom: 0-800-731-7846
    International:  +61-2-8235-5000
    Passcode:       96870349

A live webcast of the conference call and replay will be available on the investor relations page of WuXi PharmaTech's website at http://www.wuxiapptec.com .

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

Use of Non-GAAP and Pro-Forma Financial Measures

We have provided first-quarter 2008 and 2009 gross profit, operating income, net income and earnings per ADS on a non-GAAP basis, which excludes share-based compensation expenses, amortization and deferred tax impact of acquired intangible assets, and discontinued operations. The pro-forma first- quarter 2008 revenues include the January 2008 revenues from continuing operations of the AppTec business. We believe both management and investors benefit from referring to these non-GAAP and pro-forma financial measures in assessing our financial performance and liquidity and when planning and forecasting future periods. These non-GAAP operating measures are useful for understanding and assessing underlying business performance and operating trends. We expect to continue providing gross profit, operating income, and net income on a non-GAAP basis using a consistent method on a quarterly basis.

You should not view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies, and should refer to the reconciliation of non-GAAP measures to GAAP measures for the indicated periods attached hereto.

Cautionary Note Regarding Forward-Looking Statements

Statements in this release contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995, including, among others, expected 2009 operating results (including estimated total net revenue, China- based Laboratory Services and U.S. testing net revenues and related adjusted EBITDA and other trends), planned capital expenditure and investment levels, and the anticipated benefits of those efforts and the planned expansion of our service offerings and areas of related revenue growth.

These forward-looking statements are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. Our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Among other factors, continued uncertainty in the global economy and the pressures being felt by our customers and pharmaceutical industry consolidation may adversely impact our business and the trends for outsourced R&D and manufacturing for longer than expected or more severely than expected; we may be unable to successfully make our planned investments and capital expenditures on a timely basis, these investments may not yield the desired results, and we may need to modify the nature and level of our investments and capital expenditures; pharmaceutical companies may not change their business models as expected or in a manner favorable to us; we may fail to capitalize on the opportunities presented; we may not maintain our preferred provider status with our clients; and may be unable to successfully expand our capabilities to meet client needs. In addition, other factors that could cause our actual results to differ from what we currently anticipate include our limited operating history; failure to generate sufficient future cash flows or secure any required future financing on acceptable terms or at all; failure to retain key personnel; effective integration of continuing products and services from AppTec; our reliance on a limited number of customers to continue to account for a high percentage of our revenues; risk of payment failure by any of our large customers, which could significantly harm our cash flows and profitability; dependence upon the continued service of our senior management and key scientific personnel, and our ability to retain our existing customers or expand our customer base. You should read the financial information contained in this release in conjunction with the consolidated and pro-forma financial statements and related notes thereto included in our 2007 Annual Report on Form 20-F filed with and available on the Securities and Exchange Commission's website at http://www.sec.gov . For additional information on these and other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 10 of our 2007 Annual Report on Form 20-F. Our results of operations for the first-quarter 2009 are not necessarily indicative of our operating results for any future periods. All projections in this release are based on limited information currently available to us, which is subject to change. Although these projections and the factors influencing them will likely change, we undertake no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release, except as required by law. Such information speaks only as of the date of this release.

    For more information, please contact:

    WuXi PharmaTech (Cayman) Inc.
     Ronald Aldridge (for investors)
     Director of Investor Relations
     Tel:   +1-215-218-5515
     Email: ir@wuxiapptec.com

     Stephanie Liu (for the media)
     Tel:   +86-21-5046-4362
     Email: pr@wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. WuXi PharmaTech Appoints Hao Zhou as Vice President of Finance
2. Pharmatech Oncology Launches New Data Management Business Unit
3. WuXi PharmaTech Schedules Fourth Quarter 2008 Earnings Release on Thursday, March 26, 2009
4. WuXi PharmaTech Announces CFO Benson Tsang to Leave Company; COO Edward Hu Named Acting CFO
5. WuXi PharmaTech Honored on the Deloitte Technology Fast 500 Asia Pacific 2008 List for the Fifth Consecutive Year
6. WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board
7. WuXi PharmaTech to Present at 20th Annual Piper Jaffray Healthcare Conference
8. WuXi PharmaTech Expands Collaboration for Fully Integrated Services
9. WuXi PharmaTech Announces Second Quarter 2008 Results
10. WuXi PharmaTech (NYSE: WX) Appoints Mr. Steven M. Hutchins as VP of Business Development
11. Dr. Richard M. Soll Joined WuXi PharmaTech (NYSE: WX) as VP of Medicinal Chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 10, 2016 , ... Intermedix announced on Wednesday that it ... emergency medicine professional association, to support the organization's newly established physician group with ... Emergency Medicine, or AAEM, seeks to empower emergency physicians to control their own ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Wickman Agency ... to assist the local community. Pledging to select a new beneficiary every 60 ... the area. Their goal is to bring community awareness to important local causes ...
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water is excited ... bottled water brand owners that topped the list as a result of their commitment ... The premier brand was Tibet 5100, a top notch water company that specializes in ...
(Date:2/10/2016)... ... 10, 2016 , ... Dr. Jessica Barron, of Barron Family Dental in ... patients and families in the North Metro Denver area. The new dental practice focuses ... dentistry, and all in the most relaxing environment. , While some dental visits can ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... bring together more than 200 of the country’s top healthcare executives to share ... “The true benefit of the Forum is the provider-centric perspective, experience, expertise and ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... Inc. (Vanda) (NASDAQ: VNDA ), today announced financial ... year ended December 31, 2015. --> ... for Vanda with the continued growth of HETLIOZ in ... for Non-24," said Mihael H. Polymeropoulos, M.D., Vanda,s President ... product portfolio builds on this success and underscores Vanda,s ...
(Date:2/10/2016)... new report from business intelligence provider GBI Research - Alzheimer,s Disease Therapeutics ... than double from just under $5 billion in 2014 to an estimated $10.4 ... Canada , France , Germany ... UK, and Japan , and will primarily be driven by ... , France , Germany , ...
(Date:2/10/2016)...  CVS Health (NYSE: CVS ) is offering ... Santa Clara County, CA , in response to ... University campus. CVS Pharmacy stores and MinuteClinic walk-in medical ... disease. Students at Santa Clara University who have not ... anyone who has had close contact with a person ...
Breaking Medicine Technology: